Cambium Bio Unlocks US$2M+ Dental Licensing Deal with Keke Medtech

Strategic Licensing Deal Expands Cambium’s Platform

Cambium Bio Limited (ASX – CMB), a clinical-stage regenerative medicine company, has announced a significant licensing agreement with Taiwan-based Keke Medtech, Inc. The deal grants Keke exclusive worldwide rights to develop and commercialise Cambium’s proprietary human platelet lysate-derived fibrin biologic specifically for dental and oral wound-healing applications. This marks Cambium’s first out-licensing of a component of its human platelet lysate (HPL) platform beyond its core ophthalmology focus.

The fibrin biologic targets key dental indications such as post-extraction socket healing, periodontal and gum tissue regeneration, alveolar bone regeneration, and dental implant integration. The licensed territories include the United States, Southeast Asia, the Middle East, and Taiwan, positioning Cambium to tap into diverse and growing dental markets.

Financial and Development Terms Provide Non-Dilutive Capital

The agreement includes an upfront payment of US$250,000, with US$25,000 already received, alongside development milestones totaling US$1.75 million. These milestones hinge on clinical progress, including US$250,000 upon initiation of first-in-human trials within 24 months and US$1.5 million upon first regulatory approval. Cambium will also earn double-digit royalties on net sales, starting at 10% for the first US$10 million annually and increasing to 13% thereafter, plus a 20% share of sublicense revenues.

Keke assumes full responsibility for funding and conducting all development activities, including pre-clinical, clinical, and regulatory programs. This arrangement provides Cambium with valuable non-dilutive funding, strengthening its balance sheet as it advances its lead ophthalmology candidate, Elate Ocular®, into Phase 3 trials.

Maintaining Focus While Monetising Platform Potential

CEO Karolis Rosickas highlighted the strategic importance of the deal, noting it validates the broad therapeutic potential of Cambium’s HPL platform. By licensing the fibrin biologic for dental applications, Cambium can monetise its technology in complementary markets without diverting focus from its primary dry eye disease program. Additionally, Cambium retains exclusive supply rights for the fibrin biologic, ensuring ongoing revenue streams from manufacturing.

This partnership underscores Cambium’s scalable manufacturing process that extracts multiple therapeutic products from a single platform, maximising value across indications such as ophthalmology, orthopaedics, wound healing, and now dentistry.

Looking Ahead

The next steps include finalising definitive license and supply agreements within 90 days and receipt of remaining upfront payments. Meanwhile, Cambium continues to progress its Elate Ocular® Phase 3 program, with first patient dosing expected in the fourth quarter of 2025. For Keke, the challenge will be to meet clinical milestones and regulatory approvals to unlock milestone payments and royalties, validating the commercial potential of the fibrin biologic in dental care.